Phase 2 N=39 Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
Arthritis, Rheumatoid
Primary: Incidence of Adverse Drug Reaction — 3; 3; 3; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Evaluation of the Surfacer System Approach to Central Venous Access
Venous Occlusion
Primary: Number of Participants With Safe Insertion and Patency of Central Venous Access Catheter — 30 participants — p=0.5
N/A N=38 Effect of Snacks on Appetite Control
Healthy Canadians · Appetite Control
Primary: Total Area Under the Curve (AUC) for Hunger, Fullness, Desire to Eat and Prospective Consumption Using Visual Analog Scales (VAS) — 651; 1008; 638; 640 cm x min — p=<0.05
Phase 3 N=154 Mepivacaine Versus Low-Dose Bupivacaine For Primary Total Hip and Knee Arthroplasty
Knee Osteoarthritis · Hip Osteoarthritis
Primary: Time to Return of Lower Extremity Motor Function — 210.3; 184.7 minutes
N/A N=48 Effectiveness of Customized Handle Toothbrush
Dental Plaque · Dental Prophylaxis · Dental Care
Primary: Clinical Plaque Evaluation of Healthy Children and Down Syndrome of Both Groups at the Baseline — 3.05; 3.19; 3.63; 3.41 score on a scale
N/A N=13 A Comparison Between Primary and Secondary Flap Coverage in Extraction Sites: A Pilot Study
Loss of Teeth Due to Extraction
Primary: Mean Difference in Alveolar Bone Height Change — 7.5; 8.1 mm
Phase 3 N=210 Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
Double-stranded DNA Virus
Primary: Number of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA Virus — 15; 18; 39; 13 Participants
Phase 3 N=44 Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
Growth Hormone Deficiency
Primary: Annual Height Velocity (HV) After 12 Months — 9.78; 7.78 cm/year
Phase 4 N=52 IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
HIV Positive · Malnourished
Primary: Grade 3 or Higher Adverse Events Through 24 Weeks — 13; 10 Participants — p=0.40
N/A N=118 Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
Covid19
Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants
Phase 1 N=16 Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Human Immunodeficiency Virus Prevention · Human Immunodeficiency Virus (HIV)
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 1; 1; 0; 0 Participants
N/A N=64 Gastrointestinal Activation Post-elective CS (Cesarean Section) :A Comparison of Paula Method to Standard Care
Bowel Dysfunction
Primary: Time to the Resumption of Bowel Functioning as Assessed by Flatus Passage — 24.1; 39.1 hours — p=<0.05
Phase 2 N=186 Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Candida Vulvovaginitis
Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 9; 14; 13; 14 Participants
N/A N=86 School-based Physical Activity Intervention for Obesity Among Adolescents With Intellectual Disability in Hong Kong
Obesity
Primary: BMI Change — -0.14; 0.42; -0.66; 0.68 kg/m2
Phase 1 N=82 Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults
Shigellosis
Primary: Maximum Reactogenicity Per Subject and Treatment Group — 5; 12; 9; 11 Participants